Oxford BioTherapeutics to research cell therapies for Gilead...

Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers.

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Gilead’s Kite gains some height after second CAR-T approval ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T

Gilead closes in on second CAR-T approval in US

EMA starts review of second CAR-T from Gilead’s Kite unit

Ex-Kite chiefs' biotech to research 'off-the-shelf' CAR-Ts w...

Belldegrun and Chang's Allogene to take over from Pfizer in R&D deal